key: cord-0829873-vcjka1dv
authors: Lazari, L. C.; Ghilardi, F. d. R.; Rosa-Fernandes, L.; Assis, D. M.; Nicolau, J. C.; Santiago, V. F.; Dalcoquio, T. F.; Angeli, C. B.; Bertolin, A. J.; Marinho, C. R. F.; Wrenger, C.; Durigon, E. L.; Siciliano, R. F.; Palmisano, G.
title: Prognostic accuracy of MALDI mass spectrometric analysis of plasma in COVID-19
date: 2020-10-04
journal: nan
DOI: 10.1101/2020.10.01.20205310
sha: b328da3dc007991381b3b483ef5e89d3f539ba17
doc_id: 829873
cord_uid: vcjka1dv

Purpose: SARS-CoV-2 infection poses a global public health problem. There is a critical need for improvements in the noninvasive prognosis of COVID-19. We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI-TOF MS) analysis combined with bottom-up proteomic analysis of plasma proteins might identify features to predict high and low risk cases of COVID-19. Patients and Methods: We used MALDI-TOF MS to analyze plasma small proteins and peptides isolated using C18 micro-columns from a cohort containing a total of 117 cases of high (hospitalized) and low risk (outpatients) cases split into training (n = 88) and validation sets (n= 29). The plasma protein/peptide fingerprint obtained was used to train the algorithm before validation using a blinded test cohort. Results: Several sample preparation, MS and data analysis parameters were optimized to achieve an overall accuracy of 85%, sensitivity of 90%, and specificity of 81% in the training set. In the blinded test set, this signature reached an overall accuracy of 93.1%, sensitivity of 87.5%, and specificity of 100%. From this signature, we identified two distinct regions in the MALDI-TOF profile belonging to the same proteoforms. A combination of 1D SDS-PAGE and quantitative bottom-up proteomic analysis allowed the identification of intact and truncated forms of serum amyloid A-1 and A-2 proteins. Conclusions: We found a plasma proteomic profile that discriminates against patients with high and low risk COVID-19. Proteomic analysis of C18-fractionated plasma may have a role in the noninvasive prognosis of COVID-19. Further validation will consolidate its clinical utility.

The pandemic of SARS-CoV-2 infection, the etiological agent of coronavirus disease 2019 (COVID- 19) , has affected millions of people worldwide. The first case was reported in Wuhan, China and as for September 30 th , 33,722,075 people have been infected and 1,009,270 died. The ongoing outbreak is considered a pandemic (World Health Organization).

The symptoms range from mild with fever, dry cough, headache, fatigue and loss of taste and smell to severe complications including difficulty breathing or shortness of breath, chest pain and loss of speech or movement that can lead to hospitalization and death. 1 Although vaccines and small molecule treatments are in clinical trial, no definitive treatment for COVID-19 is available yet. [2] [3] [4] A mortality rate of approximately 4% has been detected in COVID-19 patients compared to 0.1% in influenza infection (World Health Organization). Due to that, it is imperative to identify patients at high risk for severe illness to assist them with supportive therapy. Markers of COVID-19 severity have been proposed. [5] [6] [7] MALDI-MS has been successfully implemented into the microbiology field building reference spectral libraries for rapid, sensitive and specific identification of bacterial and fungal species. 8 This approach is well established and accepted in many countries for routine diagnostics of yeast and bacterial infections. Viral species identification has been elucidated using similar strategies. 9 Recently, MALDI-TOF MS analysis of nasal swabs allowed sensitive and specific detection of SARS-CoV-2 infection. 10 Moreover, MALDI-TOF MS analysis of human biofluids have been proposed as diagnostic and prognostic techniques in several diseases ranging from cancer, cardiovascular, neurological and infectious diseases. [11] [12] [13] [14] [15] This study shows the identification of a plasma proteomic signature obtained from high (hospitalized) versus low (outpatients) risk patients with COVID-19 using an easy to perform, rapid and widespread technology such as MALDI-TOF MS, present in several clinical laboratories worldwide. A training and validation dataset allowed the prioritization m/z than unfractionated plasma (Supplementary Figure 3) . A comparison between three matrices showed that HCCA yielded a higher number of peaks and intensity than other matrices (Supplementary Figure 4 

Due to that, we chose to perform all analyses using a C18 fractionated sample eluting the proteins/peptides from the microcolumn using the HCCA matrix containing 50% acetonitrile and 2.5% TFA as described in the materials and methods section. To test if sample pretreatment induces potential artifacts that affect the reproducibility of the entire strategy, quadruplicate analysis of the same spot and analysis of each sample on three different preparations was performed (Supplementary Figure 6) . Two m/z regions were selected to calculate the coefficient of variance (CV) considering the sample preparation and MS acquisition variability. Within the 5700-5900 m/z region, an average of 10% CV was obtained. Within the 11300-11700 m/z region, an average of 20% CV was obtained (Supplementary Figure 7) . The lower CV in the higher m/z region is associated with the lower intensity, which increases the variance within and between samples. The CVs data obtained are in agreement with other reports using MALDI-TOF MS profiling of biofluids. [16] [17] [18] Due to that, the optimized sample preparation strategy applied to this study was based on 1ul of plasma fractionated using C18 microcolumns and proteins/peptides were eluted using HCCA matrix containing 2.5% TFA.

In the next phase, we applied the optimized strategy to plasma samples collected from COVID-19 patients. 117 patients with laboratory-confirmed COVID-19 disease were enrolled in this study, 57 with mild disease, no need for hospitalization (low risk) and 60 being admitted in the hospital (high risk). Their status was assessed using a combination of molecular, serological and clinical examination. RT-PCR and ELISA were used to test the active or past SARS-CoV-2 infection. Table 1 shows the demographic characteristics of these two groups of patients. The median age was significantly higher in the hospitalized group (52 years; IQR 39,5 -64,5) than the mild group (35 years; IQR 29 -47). A total of 40 (70%) of outpatients were female and only 28 (47%) were female in the hospitalized group. The median time of symptom onset before blood sampling was also higher in the severe group (9 days and IQR 7 -14) than in the outpatients group (4,5 days and IQR 3 -6,5 using two-tailed Mann-Whitney U-test). Four patients (3,5%) died (Supplementary Figure 8) . The sex and age distribution observed in this study is in line with the literature findings.

Indeed, a significant association between sex, age and COVID-19 disease prognosis has been reported. 19 Male patients have a higher mortality rate, hospitalizations and lower chance of recovery compared to females. [19] [20] [21] It has been shown that female patients have higher plasma levels of IL-8 and IL-18 cytokines and different immune cells number and type sustained along the life that reduce the severity of COVID-19. 22 The most prevalent symptoms in this cohort were fever and myalgia, in patients that were hospitalized with dyspnea (77%) and cough (68%) were the main clinical features. In the group of outpatients, upper respiratory signs as rhinorrhea (82%) and headache (81%) were more prevalent ( Table   2 ). The difference between groups was statistically significant (chi-square test p<0,005) regarding the type of symptom presented: as rhinorrhea (82% of the mild symptomatic patients and 22% of admitted in hospital patients), headache (81% of the mild symptomatic and 45% of hospitalized patients) and myalgia (88% of the mild symptomatic and 58% of hospitalized patients) being more prevalent in patients not requiring hospitalization. On the other hand, dyspnea was present in only 22% of the mild symptomatic patient and in 77% of the patients that were admitted in a hospital (p<0,005). Patients with a mild presentation of COVID-19 (low risk) presented running nose, headache and myalgia and did not develop the inflammatory syndrome. This group of patients were more attentive to their first symptoms and search for health care earlier (most of them are healthcare professionals which may represent a bias). The most All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint prevalent comorbidities found in our patients were obesity (4% of the mild group and 27% of the hospitalized group) and dyslipidemia (5% of the mild group and 17% of the hospitalized group). Although there was no difference in dyslipidemia´s prevalence between both groups we found a higher number of obese patients (BMI > 30) between people requiring hospitalization (16/60 = 27%), Supplementary Table 1. It is important to mention that this survey was done at INCOR hospital, an institution specialized in heart and lung diseases, so we did find a higher prevalence of cardiovascular diseases than in the general population (as heart transplantation patients and people with chronic conditions).

MALDI-TOF spectra obtained from the C18 fractionated plasma from the high and low risk groups were analyzed, as described in the Materials and Methods section. Analyzing the 117 plasma samples, the data preprocessing yielded a total of 63 peaks detected, which dropped to 38 after the Wilcoxon rank sum test with a p-value < 0.05. After Ig filtering, 5 total peaks were identified (Supplementary Table 2 ). PCA analysis of significant peaks and Ig filtered peaks are presented in Figure 2 . The Ig filtering demonstrated a better separation than the PCA with all significant peaks.

The MS peaks were analyzed using six machine learning algorithms to discriminate between the two conditions under optimized parameters (Supplementary Table 3 ). In general, all models did not differ significantly from each other, and presented a robust behavior comparing each fold. The results of the six tested models in the dataset without Ig filtering showed that the RF model had the higher mean area under the curve (AUC) for the ROC curve (0.95) ( Figure 3A) ; additionally, SVM-P and RF had the lowest standard deviation for AUC values between each fold (Supplementary Table   4 , 5). Thus, the RF model was considered to have the best performance of the six tested and was applied to the test set.

For Ig filtering approach, RF had the highest mean AUC for ROC (0.94) with a low standard deviation between each fold ( Figure 3B) ; so it was considered the model with the best performance for Ig filtered peaks. The best parameter for RF is mtry=2 for both. It is worth mentioning that KNN, NNET, SVM-P and SVM-R also had good performances. The ROC and PR curves of the training set for Ig filtered and non-filtered peaks, together with the mean accuracy, mean sensitivity and mean specificity of the prediction in the validation set in each fold ( Figure 3C and D). Table 6 and 7). Serum albumin, serotransferrin, complement C3a, alpha-2 macroglobulin and haptoglobin were among the proteins with the highest PSMs. These proteins have molecular weights (MW) higher than 15kDa, which is the MW cutoff of the gel band analyzed. A total of 52 proteins were identified with a MW between 10-15kDa. Within them, four proteins, platelet factor 4 (PF4), immunoglobulin lambda variable 4-69 (IGLV4-69), serum amyloid A-1 (SAA1) and serum amyloid A-2 (SAA2) were upregulated in the high compared to low risk groups. The MALDI-TOF MS peaks at 11443, 11530 11683 Da correspond to truncated fragments originating from serum amyloid A1 ( Table 3) . The MALDI-TOF peaks at 11633, 11476 and 11393 Da correspond to truncated fragments originating from serum amyloid A2 ( Table 3) . The peptide 20-SFFSFLGEAFDGAR-33 peptide, shared between SAA1 and SAA2, was identified in the LC-MS/MS analysis and constitutes the initial sequence of one truncated form. The R19 was cleaved by trypsin during processing and constitutes the first amino acid of the other truncated form. The 21-FFSFLGEAFDGAR-33 semi-tryptic peptide, shared between SAA1 and SAA2, was also identified and constitutes the initial sequence of the other truncated form (Supplementary Table   7 ). Moreover, the semi-tryptic peptides 23-SFLGEAFDGAR-33 and 24-FLGEAFDGAR-33 were identified, suggesting the presence of another two low abundant proteoforms, which were not detected in the MALDI-TOF MS spectra. These sequences were consistent with the molecular weights of the discriminatory m/z values identified upregulated in the plasma samples collected from COVID-19 patients with high risk.

We describe the application of MALDI-TOF MS to identify a protein signature specific to COVID-19 patients with high and low risk, based on clinical symptoms, using 1ul of C18 fractionated plasma. This study was based on the supposition that SARS-CoV-2 infection induces a systemic response that changes selectively the plasma protein expression, allowing a discrimination between patients at high risk (need of hospitalization) compared to low risk ones (outpatient treatment). Using machine learning algorithms with optimized parameters, an overall accuracy of 93.1%, a sensitivity of 87.5%, and a specificity of 100% was achieved separating the two groups. The sample preparation, data acquisition and analysis parameters were optimized and validated to understand their influence of these factors in creating systemic biases. We confirmed that these factors were not influencing the accuracy of our approach based on the CVs detected. CVs reported in this study confirm similar reports from other research groups. 17, 23, 24 The overfitting issue, normally seen in these approaches, was minimized using independent datasets for the training and the validation.

Moreover, the test dataset was analyzed only once based on the results from the training set avoiding subjective selection of the best results. In this study, we were interested in determining a specific protein or a panel of proteins that could be used for COVID-19 prognosis. Applying a combination of gel electrophoresis and nLC-MS/MS, we identified SAA1 and SAA2 proteoforms as regulated discriminatory proteins. These two proteins are involved in the acute phase response. Proteins involved in the acute phase response are increased early during viral and bacterial infections. Serum amyloid A-1 (SAA1) and A-2 (SAA2) are acute phase reactants synthesized by the liver and secreted into the bloodstream inflammatory and oncogenic processes. 25 Extra-hepatic SAA protein synthesis has been reported in inflamed tissues. 26, 27 SAA represents a family of high-density lipoproteins with 103-104 amino acids sharing high sequence homology between the different members. Four isoforms are expressed in humans SAA1, SAA2, SAA3 and SAA4. 25,28 During infection, SAA protein production and secretion in the circulation can increase more than 1000-fold suggesting an early response to infection. However, sustained expression of SAA proteins is associated with chronic pathological conditions. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint SAA1 was already reported to be differentially expressed in patients with severe. 29, 30 The SAA1 and SAA2 proteins were also identified upregulated in severe COVID-19 patients in a clinical cohort from China. 31 The authors used large scale LC-MS/MS analysis of serum samples to identified differentially regulated proteins and metabolites as potential prognostic markers. 31 The identification of SAA1 and SAA2 as potential markers confirms our study.

A specific correlation between SAA proteins and CRP has been found in several infectious diseases with the concentration of SAA increasing up to 2000mg/L. 32 However, SAA proteins were found to be more sensitive than CRP in detecting variation in the inflammatory status of infected patients. 33 Due to that, increased levels of SAA1 and SAA2 proteoforms can be seen as a measure of the increased severity of the disease and so on prognostic factors. Due to its ubiquitous expression in several infectious diseases, SAA proteins cannot be associated directly with the SARS-CoV-2 and should be complemented with other viral specific molecular tests.

A possible mechanism of increase of SAA proteins in severe COVID-19 patients could be due to the cytokine storm that is elicited during the infection. Indeed, increased levels of cytokines such as interleukin IL-2, IL-7, GCSF, interferon-γ inducible protein 10, MCP 1, MIP 1-α, and TNF-α and IL-6 is associated with COVID-19 disease severity, suggesting that the mortality observed could be due to virally/induced hyperinflammation. 34 The elevation of IL-1 and IL-6 increase synergistically the levels of SAA proteins synergistically. At the same time, SAA proteins increase the expression of IL-1β mediated by NLRP3 in human and mouse immune cells. 35, 36 SARS-CoV ORF8b activates the NLRP3 inflammasome inducing the secretion of active IL-1β and IL-18. 37 Moreover, SARS-CoV ORF3a activates the NLRP3 inflammasome by promoting TNF receptor-associated factor 3 (TRAF3)-ubiquitination of p105 and activation of NF-kB and subsequent transcription and secretion of IL-1β. 38 Overactivation of NLRP3 in SARS-CoV-2 infection has been postulated delineating specific pathways for its activation [39] [40] [41] . Blockade of NFκB, a central player in the SAA-mediated activation of proinflammatory cytokines, could represent a novel therapeutic target for severe cases of COVID-19. Due to that, SAA proteins might play a critical role in SARS-CoV-2 infection as an early response to inflammation but also can be seen as pro-inflammatory proteins to amplify the cytokine storm. Although comprehensive LC-MS/MS analysis has been performed using sera from COVID-19 patients, a proteomic fingerprint using MALDI-TOF MS on plasma samples has not been reported. Recently, MALDI-TOF MS combined with a machine learning approach was used to detect SARS-CoV-2 in nasal swabs from infected patients. 42 The application of RT-PCR, immunochromatography and recently MALDI-TOF MS have been used and proven to be reliable for the diagnosis of SARS-CoV-2 infection. However, no method exists so far to discriminate between high and low risk patients. This study shows that MALDI-TOF MS combined with machine learning algorithms offers a reproducible, easy to use, fast, low cost technique that can be implemented by several researchers worldwide to test the reliability of this marker. Moreover, the widespread use of MALDI-TOF in clinical laboratories will allow an easy transition into the hospitals.

This study has focused on the fractionated plasma focusing on a limited mass range 2000-20000. Moreover, the concomitant ionization of proteins/peptides in this region limits the detection of low abundant ones. Improved large scale shotgun approaches combined with extensive fractionation have been applied to identify potential COVID-19 biomarkers and could be used in association with SAA1 and SAA2 provided in this study to create a panel of more reliable biomarkers. Association of the current biomarkers with other biomarkers will offer the possibility to improve the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint prognostic accuracy. Further validation in prospectively collected samples, as well as proof of added value to the existing noninvasive diagnostic strategies.

A larger independent cohort of patients should be analyzed to corroborate these findings. Inter-laboratory studies across countries should be performed to validate these data. Moreover, a time-course study during the development of the infection would give more information on the validity of these markers as early prognostic markers.

This study analyzed a retrospective case-series cohort. No patients were involved in the study design, setting the research questions, or the outcome measures directly. No patients were asked to give advice on interpretation or writing up of results. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint Figure 3 : Four-fold nested cross validation of the training set for model selection. A) best AUC values for ROC and PR curves of each model with the non-filtered dataset. In B, best AUC values for ROC and PR curves of each model with the Ig filtered dataset. In C, the average accuracy, specificity and sensibility of all folds for non-filtered peaks. In D, the average accuracy, specificity and sensibility of all folds for Ig filtered peaks.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint Figure 4 : Training results of the model with best performance (RF) and the prediction results of the test set.

In A and B boxes, the ROC and PR curves of the training step for the dataset without Ig selection and with Ig selection, respectively. C) the metrics of the confusion matrix from the test set prediction of both approaches. D) the confusion matrix of the prediction for the model without Ig filtering. E) the confusion matrix of the prediction for the model with Ig filtering.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 4, 2020. . perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 4, 2020. . https://doi.org/10.1101/2020.10.01.20205310 doi: medRxiv preprint 

Supplementary Table 1 . Comorbidities associated with the 117 COVID-19 patients investigated in this study.

Supplementary Table 2 : mass peaks (m/z) selected in the data preprocess step using Wilcoxon test and FSelector package.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 4, 2020. Table 6 : Total proteins identified in the 10-15kDa region of C18 fractionated plasma collected from patients with high and low risk. Table 7 : Total peptides identified in the 10-15kDa region of C18 fractionated plasma collected from patients with high and low risk.

World Health Organization declares global emergency : A review of the 2019 novel coronavirus ( COVID-19 )

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus ( 2019-nCoV ) in vitro

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Angiotensin -converting enzyme 2 ( ACE2 ) as a SARS -CoV -2 receptor : molecular mechanisms and potential therapeutic target

Mild versus severe COVID-19: Laboratory markers

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study

Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv

MALDI-TOF mass spectrometry: An emerging technology for microbial identification and diagnosis

Application of MALDI-TOF Mass Spectrometry in Clinical Virology: A Review

A Combined approach of MALDI-TOF Mass Spectrometry Authors

MS for the diagnosis of infectious diseases

Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry

Detection of colorectal cancer using MALDI-TOF serum protein profiling

A label-free method based on MALDI-TOF mass spectrometry for the absolute quantitation of troponin T in mouse cardiac tissue

HDL in humans with cardiovascular disease exhibits a proteomic signature

Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis

Enhancement in MALDI-TOF MS analysis of the low molecularweight human serum proteome

Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry

Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis

Impact of sex and gender on COVID-19 outcomes in Europe

Biological sex impacts COVID-19 outcomes

Sex differences in immune responses that underlie COVID-19 disease outcomes

Serum Peptide Profiling by Magnetic Particle-Assisted, Automated Sample Processing and MALDI-TOF Mass Spectrometry

Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer

Acute Serum Amyloid A Induces Migration, Angiogenesis, and Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model

Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function

Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide

Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome

Serum Amyloid A Is Not Useful in the Diagnosis of Severe Acute Respiratory Syndrome

Proteomic and Metabolomic Characterization of COVID-19

Correlations between serum amyloid A protein and C-reactive protein in infectious diseases

Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases

COVID-19: consider cytokine storm syndromes and immunosuppression

Serum amyloid a induces NLRP-3-mediated IL-1β secretion in neutrophils

Serum amyloid a-mediated inflammasome activation of microglial cells in cerebral ischemia

SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells

Targeting the NLRP3 Inflammasome in Severe COVID-19

Severe COVID-19: NLRP3 Inflammasome Dysregulated

Detection of SARS-CoV-2 in nasal swabs using MALDI-MS

 Supplementary Figure 7 : MALDI-TOF MS analysis in positive and linear mode of 5 patient plasma samples analyzed using 3 independent sample preparations and 4 acquisitions from each spot (total 12 spectra per patient). The intensities of peaks present in two selected mass regions, 5700-5900 and 11300-11700 m/z were analyzed. a Relative Intensity ± standard deviation; b Coefficient of Variation; c Peak Frequencycalculated from 12 spectra (3 prepared replicates and 4 spectra from each preparation) for peaks with a